Read by QxMD icon Read


Matthijs Cysouw, Esther Bouman-Wammes, Otto Hoekstra, Alfons van den Eertwegh, Maartje Piet, Jeroen van Moorselaar, Ronald Boellaard, Max Dahele, Daniela Oprea-Lager
PURPOSE: To investigate the predictive value of [18 F]-fluoromethylcholine positron emission tomography/computed tomography (PET/CT)-derived parameters on progression-free survival (PFS) in oligometastatic prostate cancer patients treated with stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: In [18 F]-fluoromethylcholine PET/CT scans of 40 consecutive patients with ≤4 metachronous metastases treated with SBRT we retrospectively measured the number of metastases, standardized uptake values (SUVmean , SUVmax , SUVpeak ), metabolically active tumor volume (MATV), and total lesion choline uptake...
February 13, 2018: International Journal of Radiation Oncology, Biology, Physics
Rami A El Shafie, Angela Paul, Denise Bernhardt, Kristin Lang, Thomas Welzel, Tanja Sprave, Adriane Hommertgen, Johannes Krisam, Daniela Schmitt, Sebastian Klüter, Kai Schubert, Christina Klose, Meinhard Kieser, Jürgen Debus, Stefan Rieken
BACKGROUND: Stereotactic radiosurgery (SRS) of brain metastases (BM) is recommended in oligometastatic scenarios as a less toxic treatment alternative to whole-brain radiotherapy. Recent findings support SRS for patients with multiple (>3) BM. Furthermore, advances in MR imaging have facilitated the detection of very small BM, as advances in SRS technology have facilitated the highly conformal and simultaneous treatment of multiple target lesions. OBJECTIVE: To compare efficacy and toxicity of repeated frameless robotic SRS of up to 10 simultaneous BM through a single-center prospective randomized trial...
March 15, 2018: Neurosurgery
Kadri Altundag
No abstract text is available yet for this article.
January 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
Devin Vaswani, Adam N Wallace, Preston S Eiswirth, Thomas P Madaelil, Randy O Chang, Anderanik Tomasian, Jack W Jennings
PURPOSE: To evaluate the effectiveness of percutaneous image-guided thermal ablation in achieving local tumor control and pain palliation of sarcoma metastases within the musculoskeletal system. MATERIALS AND METHODS: Retrospective review of 64 sarcoma metastases within the musculoskeletal system in 26 women and 15 men (total = 41) treated with ablation between December 2011 and August 2016 was performed. Mean age of the cohort was 42.9 years ± 16.0 years...
March 14, 2018: Cardiovascular and Interventional Radiology
Eugene Shenderov, Michael A Gorin, Seohyun Kim, Pamela T Johnson, Mohamad E Allaf, Alan W Partin, Martin G Pomper, Emmanuel S Antonarakis, Kenneth J Pienta, Steven P Rowe
Radiotracers targeting prostate-specific membrane antigen (PSMA), including [18 F]DCFPyL, have been extensively investigated as a means to image prostate cancer more accurately. We present the case of a man with oligometastatic prostate cancer who was also diagnosed with a metastatic small bowel carcinoid tumor following the detection of indeterminate findings on a [18 F]DCFPyL PET and discuss how this case highlights the utility of a newly proposed reporting system for PSMA-targeted PET (PSMA-RADS version 1...
March 2018: Urology Case Reports
Rami A El Shafie, Angela Paul, Denise Bernhardt, Henrik Hauswald, Thomas Welzel, Tanja Sprave, Adriane Hommertgen, Johannes Krisam, Daniela Schmitt, Sebastian Klüter, Kai Schubert, Christina Klose, Meinhard Kieser, Jürgen Debus, Stefan Rieken
BACKGROUND: Neurosurgical resection is recommended for symptomatic brain metastases, in oligometastatic patients or for histology acquisition. Without adjuvant radiotherapy, roughly two-thirds of the patients relapse at the resection site within 24 mo, while the risk of new metastases in the untreated brain is around 50%. Adjuvant whole-brain radiotherapy (WBRT) can reduce the risk of both scenarios of recurrence significantly, although the associated neurocognitive toxicity is substantial, while stereotactic radiotherapy (SRT) improves local control at comparably low toxicity...
March 8, 2018: Neurosurgery
Saeed Dabestani, Christian Beisland, Grant D Stewart, Karim Bensalah, Eirikur Gudmundsson, Thomas B Lam, William Gietzmann, Paimaun Zakikhani, Lorenzo Marconi, Sergio Fernandéz-Pello, Serenella Monagas, Samuel P Williams, Christian Torbrand, Thomas Powles, Erik Van Werkhoven, Richard Meijer, Alessandro Volpe, Michael Staehler, Börje Ljungberg, Axel Bex
BACKGROUND: Optimal follow-up (FU) strategy to detect potentially curable (PC) recurrences after treatment of localised clear cell renal cell carcinoma (ccRCC) is unclear. This study retrospectively analysed a large international database to determine recurrence patterns and overall survival (OS), as part of a wider project to issue recommendations on FU protocols. OBJECTIVE: To analyse associations between RCC recurrences in patients with ccRCC, their risk group stratifications, treatments, and subsequent outcomes...
March 7, 2018: European Urology Focus
Dominik Schulz, Markus Wirth, Guido Piontek, Andreas Knopf, Christoph Straube, Steffi Pigorsch, Stephanie E Combs, Anja Pickhard
PURPOSE: While metastases directed therapy for oligometastatic disease is recommended in different cancer entities, the treatment of solitary metastases in head and neck squamous cell carcinoma (HNSCC) patients is not clearly defined. METHODS: A retrospective analysis was performed on data from 143 HNSCC patients treated between 2001 and 2016 in a tertiary university hospital. Clinical factors and outcome were measured using the median survival of patients receiving metastases specific therapy in comparison with matched control patients...
March 8, 2018: European Archives of Oto-rhino-laryngology
R J Klement, J Hoerner-Rieber, S Adebahr, N Andratschke, O Blanck, J Boda-Heggemann, M Duma, M J Eble, H C Eich, M Flentje, S Gerum, P Hass, C Henkenberens, G Hildebrandt, D Imhoff, K H Kahl, N D Klass, R Krempien, F Lohaus, C Petersen, E Schrade, T G Wendt, A Wittig, M Guckenberger
BACKGROUND: Stereotactic body radiotherapy (SBRT) for oligometastatic disease is characterized by an excellent safety profile; however, experiences are mostly based on treatment of one single metastasis. It was the aim of this study to evaluate safety and efficacy of SBRT for multiple pulmonary metastases. PATIENTS AND METHODS: This study is based on a retrospective database of the DEGRO stereotactic working group, consisting of 637 patients with 858 treatments...
March 3, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Jürgen Dunst, René Baumann
No abstract text is available yet for this article.
March 5, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Young Hong, Jonathan Rice, Divyansh Sharma, Robert C G Martin
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) often presents late with only 20% of patients being candidates for resection while majority already have advanced metastases with median overall survival of 3-6 months. Currently, the role of oligometastasectomy and local therapy options in PDAC is unknown in patients who have favorable response to systemic chemotherapy. The aim of this study is to analyze the survival outcome of oligometastasectomy and local IRE therapy in select patients who are treated with systemic chemotherapy for PDAC metastases...
March 2, 2018: American Journal of Surgery
Alexandru Filipescu, Irina Balescu, Nicolae Bacalbasa
Upper abdominal involvement in recurrent cervical cancer usually occurs as part of systemic disease and is most often amenable to palliative chemotherapy. However, in certain cases in which oligometastatic disease is proven, surgery might be considered. We present a case series of six patients submitted to surgery for upper abdominal oligometastases with cervical origin. The main surgical procedures performed included atypical hepatectomy (in five cases) and splenectomy (in one case). In all cases, the cervical origin of the lesions was revealed by histopathological studies...
March 2018: Anticancer Research
Thomas G Bird, Samuel Y Ngan, Julie Chu, René Kroon, Andrew C Lynch, Alexander G Heriot
PURPOSE: Radical management of locally recurrent rectal cancer (LRRC) can lead to prolonged survival. This study aims to assess outcomes and identify prognostic factors for patients with LRRC treated using a multimodality treatment protocol. METHODS: An analysis of a prospectively maintained institutional database of consecutive patients who underwent radical surgical resection for LRRC was performed. Potential prognostic factors were investigated using a Cox proportional hazards model...
February 21, 2018: International Journal of Colorectal Disease
Young Kwok, Adeel Kaiser, Stephanie R Rice, Randi Cohen, Mark Mishra
PURPOSE OF REVIEW: The overview summarizes recent developments in radiation oncology for high risk and recurrent prostate cancer. RECENT FINDINGS: A number of well known phase III prostate hypofractionated radiation therapy (HFxRT) trials were finally published with long-term follow-ups. These trials demonstrate patterns of equivalent tumor control with several showing worse toxicity rates. The ASCENDE-RT randomized trial demonstrated the superiority of brachytherapy boost in intermediate and high-risk prostate cancer...
February 19, 2018: Current Opinion in Oncology
Kimberly A Maciolek, E Jason Abel, Sara L Best, Hamid Emamekhoo, Sarah L Averill, Timothy J Ziemlewicz, Meghan G Lubner, J Louis Hinshaw, Fred T Lee, Shane A Wells
PURPOSE: The purpose of the article is to evaluate the safety and oncologic efficacy of microwave ablation for metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS: From September 2011 to December 2016, 33 mRCC were ablated in 18 patients using percutaneous microwave ablation. Sites of mRCC include retroperitoneum (n = 12), contralateral kidney (n = 6), liver (n = 6), lung (n = 5), adrenal gland (n = 5). Technical success, local, and distant tumor progression, and complications were assessed at immediate and follow-up imaging...
February 20, 2018: Abdominal Radiology
Christopher M Jones, Alessandro Brunelli, Matthew E Callister, Kevin N Franks
Purpose of review: The majority of patients with non-small cell lung cancer (NSCLC) present with advanced disease and overall survival rates are poor. This article outlines the current and outstanding evidence for the use of multimodality treatment in this group of patients, including in combination with an increasing number of treatment options, such as immunotherapy and genotype-targeted small molecule inhibitors. Recent findings: Optimal therapy for surgically resectable stage III disease remains debatable and currently the choice of treatment reflects each individual patient's disease characteristics and the expertise and opinion of the thoracic multi-disciplinary team...
2018: Current Surgery Reports
Vanessa Figlia, Rosario Mazzola, Francesco Cuccia, Filippo Alongi, Gianluca Mortellaro, Daniela Cespuglio, Teresa Cucchiara, Giuseppina Iacoviello, Vito Valenti, Massimo Molino, Francesco Verderame, Domenica Matranga, Antonio Lo Casto, Giuseppe Ferrera
BACKGROUND: Several experiences in the literature report SBRT as an effective treatment option for medically inoperable early stage non-small cell lung cancer (NSCLC) and oligometastatic disease. The optimal fractionation schedules and total dose remain controversial. In this study, we evaluated the safety in terms of toxicity and efficacy of using of 8-10 fractions schedules with Helical Tomotherapy (HT) for primary and metastatic lung lesions. METHODS: Between March 2014 and May 2016, a total of 39 patients (median age 72 years, range 26-91) were treated with HT-SBRT for malignant lung lesions: 22 patients with early stage NSCLC, 17 with oligometastases...
February 17, 2018: La Radiologia Medica
Suresh Senan, Chad G Rusthoven, Ben J Slotman, Shankar Siva
This review highlights key publications and abstracts in the field of radiation oncology for lung cancer in 2017 and attempts to place these in the context of developments for the broader thoracic oncology community.
February 13, 2018: Journal of Thoracic Oncology
Prasanna Sooriakumaran
No abstract text is available yet for this article.
February 12, 2018: BJU International
Maureen L Aliru, Jonathan E Schoenhals, Bhanu P Venkatesulu, Clark C Anderson, Hampartsoum B Barsoumian, Ahmed I Younes, Lakshmi S K Mahadevan, Melinda Soeung, Kathryn E Aziz, James W Welsh, Sunil Krishnan
Radiotherapy is a component of the standard of care for many patients with locally advanced nonmetastatic tumors and increasingly those with oligometastatic tumors. Despite encouraging advances in local control and progression-free and overall survival outcomes, continued manifestation of tumor progression or recurrence leaves room for improvement in therapeutic efficacy. Novel combinations of radiation with immunotherapy have shown promise in improving outcomes and reducing recurrences by overcoming tumor immune tolerance and evasion mechanisms via boosting the immune system's ability to recognize and eradicate tumor cells...
February 1, 2018: Immunotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"